Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatment

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Harriman, Gregory ^a   Harper, Lesley K ^a   Schaible, Thomas F ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG RESEARCH; HUMAN; IMMUNOTHERAPY; INFLAMMATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032703263     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
2. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995;7:251-9.
3. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor a antibody (infliximab) therapy profoundly down-regulates the inflammation inCrohn's ileocolitis. Gastroenterology 1999;116:22-8
4. D'haens G, van Deventer S, van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-rumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116: 1029-34
5. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337:1029-35.
6. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas inpatients with Crohn's disease. N Engl J Med 1999;340:1398-405.
7. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
8. Elliot MJ, Maini RN, Feldmann M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.